Outcomes of 25 Gynecologic Cancer Patients with Brain Metastasis: A Single Center Experience

Serhat Comert1*, Mehmet Nur Altınörs2

1Department of Neurosurgery, Yenimahalle Training and Research Hospital, Ankara, Turkey
2Department of Neurosurgery, School of Medicine, Başkent University, Ankara, Turkey

*Corresponding Author: Serhat Comert, Department of Neurosurgery, Yenimahalle Training and Research Hospital, Yeni Batı Mah. 2026. Cad. 2367. Sok. No: 406560 Yenimahalle, Ankara, Turkey.

Abstract
Gynecologic malignancy is the second most common cancer in elderly women. These cancers usually spread locally at first, and distant metastatic sites. The brain is not a usual site of metastatic involvement. However, we present 25 gynecologic cancer cases with brain metastasis. The study included 25 cases with various gynecologic malignancies that were retrospectively analyzed. Therapeutic modalities, survival and time between the initial surgery and brain metastasis were recorded. Mean survival was 48.5 months for 25 patients with ovarian cancer versus 32.4 months in those with other gynecological cancers. At the time of brain metastasis, the CA-125 level was elevated in all the patients, except 4 whom had cervical cancer. Mean CA-125 level was 202 IU mL−1. There were not any differences in mean overall survival between the patients who underwent surgical resection and those received medical treatment. Brain metastasis can occur in all gynecologic cancers and has a poor prognosis, despite multimodal treatment.

Keywords: Gynecologic cancers, brain metastasis, ovarian carcinoma, cervical carcinoma, endometrial carcinoma

1. INTRODUCTION
Brain metastasis is common in patients with leukemia, lymphoma, lung cancer and breast cancer; however, metastasis to the brain in patients with gynecologic malignancies is uncommon, except for choriocarcinoma [1, 2]. Epithelial ovarian carcinoma (EOC) is one of the most common gynecologic malignancies and has similar clinical prognosis as primary peritoneal carcinoma (PPC) [3]. Brain metastasis in EOC and PPC cases are rare and usually present as a late manifestation in patients with prolonged survival. The incidence of brain metastasis in EOC ranges from 0.29% to 5% [4-7]. Only 2 case of primary peritoneal adenocarcinoma metastasis to the brain have been reported [8, 9]. Endometrial adenocarcinoma is the most common gynecologic malignancy and has a low incidence of metastasis to the brain; ranging from 0.3% to 1.4% [10, 11]. Metastatic disease to the CNS from other gynecological malignancies, such as cervical cancer, uterine sarcomas and vulvar cancer is extremely rare. For example, only a few reports of brain metastasis in vulvar carcinoma patients have been published in the English language literature [12, 13]. We report the radiological findings, treatment modalities, outcomes, and survival in 25 gynecological cancer patients with metastasis to the brain that were treated between 2007 and 2017 at the Başkent University Department of Gynecologic Oncology.

2. MATERIALS AND METHODS
This retrospective study included gynecological cancer patients with metastasis to the brain that were treated at Başkent University between January 2007 and January 2017. The retrospective design of the study eliminated the necessity of ethical committee approval. Pathologic classification of the cancers, treatment regimens, time from onset of disease to detection of brain metastasis, extracranial metastasis and time of occurrence, changes in the CA-125 level, and overall survival (OS) are provided, along with brain imaging findings. Additionally, survival and factors involved in prognosis are discussed. SPSS v.17 was used for statistical analysis. Dichotomous variables were
analyzed using the chi-square test and numeric variables were analyzed using the t-test. P values < 0.05 were considered statistically significant.

3. RESULTS

3.1. Ovarian Carcinoma

Among 657 patients with EOC, 11 (mean age: 57 years; range: 45-74 years) developed brain metastasis. In all, 8 of these 11 patients had serous adenocarcinoma and 2 had clear cell adenocarcinoma. All 11 patients underwent cytoreductive surgery performed by an experienced gynecologic oncology team. All 9 patients with serous adenocarcinoma had stage IV cancer, and received paclitaxel and carboplatin as first-line chemotherapy. Only 2 of the serous adenocarcinoma patients achieved remission without recurrence during 12 months of follow-up; the 9 other patients had disease-free survival (DFS) of 9 months. Other chemotherapeutic agents, including liposomal doxorubicin, gemcitabine, topotecan, weekly paclitaxel, and oral tamoxifen, were used one by one in the mentioned order until recurrence occurred or an increase in CA-125 was observed.

Mean Ca-125 level was 237 IU mL⁻¹ (range: 2-735 IU mL⁻¹) at the time CNS metastasis was noted. Mean survival after cytoreduction in the stage IV cancer patients was 43.9 months (range: 27-79 months); following brain metastasis mean survival was limited to 2.78 months (range: 0-9 months), regardless of the therapy used. The four patients that underwent surgical resection due to cranial metastasis had OS of 4.3 months following surgery. The other 3 patients opted for medical treatment and had OS of 2.2 months. Among the 3 patients that were surgically treated, 7 had cranial recurrence and again underwent surgery. The difference between treatment regimens was significant (P = 0.605). Results in the patients with stage III cancer were similar; OS was 39 and 2 months following diagnosis and surgical resection, respectively.

Table 1. Features of patients with gynecologic cancers metastasize to brain

<table>
<thead>
<tr>
<th>Type of gynecological malignancies</th>
<th>Number of sites involved in CNS</th>
<th>Operation status</th>
<th>Radiotherapy status for brain metastasis</th>
<th>Interval between initial and second diagnosis / Survival after brain metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient A Ovarian serous carcinoma</td>
<td>2 sites</td>
<td>NA</td>
<td>NA</td>
<td>34 m / 4 m</td>
</tr>
<tr>
<td>Patient B Ovarian serous carcinoma</td>
<td>1 site</td>
<td>Operated</td>
<td>RT</td>
<td>26m / 9m (alive)</td>
</tr>
<tr>
<td>Patient C Ovarian serous carcinoma</td>
<td>2 sites</td>
<td>Operated</td>
<td>RT</td>
<td>72 m / 6 m</td>
</tr>
<tr>
<td>Patient D Ovarian serous carcinoma</td>
<td>2 sites</td>
<td>Operated</td>
<td>RT</td>
<td>28 m / 4 m</td>
</tr>
<tr>
<td>Patient E Ovarian serous carcinoma</td>
<td>1 site</td>
<td>NA</td>
<td>NA</td>
<td>36 m / 7 d</td>
</tr>
<tr>
<td>Patient F Ovarian clear cell carcinoma</td>
<td>4 sites</td>
<td>NA</td>
<td>NA</td>
<td>35 m / 2 m</td>
</tr>
<tr>
<td>Malignant mixed Mullerian tumor</td>
<td>2 sites</td>
<td>NA</td>
<td>NA</td>
<td>5 m / 2 m</td>
</tr>
<tr>
<td>Endometrial carcinoma (Endometroid)</td>
<td>2 sites</td>
<td>Only biopsy</td>
<td>RT</td>
<td>29m / 30m (alive)</td>
</tr>
<tr>
<td>Endometrial carcinoma (Serous)</td>
<td>1 site</td>
<td>NA</td>
<td>NA</td>
<td>2 m / 5 m</td>
</tr>
<tr>
<td>Primary Peritoneal carcinoma</td>
<td>3 sites</td>
<td>NA</td>
<td>NA</td>
<td>13 m / 2 m</td>
</tr>
<tr>
<td>Cervical carcinoma</td>
<td>1 site</td>
<td>Operated</td>
<td>RT</td>
<td>4 m / 1 m</td>
</tr>
<tr>
<td>Vulvar carcinoma</td>
<td>4 sites</td>
<td>NA</td>
<td>NA</td>
<td>36 m / 12 d</td>
</tr>
</tbody>
</table>

(NA: Not applicable, RT: Radiotherapy, m: Months, d: Days)

3.2. Other Gynecologic Malignancies

In all, 368 patients with endometrial cancer underwent various surgical and medical treatments during the study period, 4 of which developed brain metastasis; histopathological types were endometrioid and serous papillary adenocarcinoma. Both patients underwent initial staging and cytoreductive surgery. The patient with serous papillary cancer was stage I B, grade 3 and the patient with an endometrioid tumor was stage III A, grade 3. Both patients received 6 cycles of paclitaxel and carboplatin (175 mg/ m² dose for paclitaxel, AUC 5 dose for carboplatine) following cytoreduction.
Metastatic disease to the brain occurred with synchronous disseminated abdominal spread in both patients. Elevated CA-125 was observed in these 5 patients (163 IU mL⁻¹) at the time CNS involvement was noted.

During the study period we treated 15 malignant mixed Mullerian tumor (MMMT) patients; 3 patients had stage 4 disease and developed brain metastasis 7 months after initiation of cisplatin and liposomal doxorubicin. Imaging methods, including abdominal and thoracic tomography, showed concomitant lung metastasis and disseminated abdominal spread. Survival following brain metastasis was only 3 months.

One of 256 patients with cervical carcinoma treated during the study period developed cranial metastasis; the patient underwent type-3 hysterectomy, and bilateral pelvic and para-aortic lymph node dissection following 28 d of chemoradiation with 6 cycles of platin-based chemotherapy. Histopathologic evaluation showed both pelvic and para-aortic lymph nodes consistent with clear cell adenocarcinoma. DFS was 24 months prior to the occurrence of brain metastasis, after which time the patient survived 1 month.

Of the 34 patients with PPC, 3 had brain metastasis during the study period. The treatment administered to this patient was similar to that given to EOC patients; following cytoreductive surgery, chemotherapy consisting of paclitaxel and carboplatin was administered. DFS was 6 months prior to recurrence. Although the time between the initiation of the therapy and brain metastasis was 13 months, survival after brain metastasis was 1.5 months. Among the 46 patients with vulvar carcinoma, 2 had brain metastasis (squamous cell adenocarcinoma). The patient first underwent surgery at another hospital in 2006, but following recurrence in 2007 vulvectomy and bilateral inguinal lymph node dissection were performed at our hospital. This patient was stage 3 (FIGO). She received 5000 cGy of pelvic radiotherapy concomitant with 3 cycles of cisplatin and doxorubicin. DFS before brain metastasis was 2.3 months; survival after brain metastasis was less than 1 month.

3.3. Clinical Imaging

The brain metastases observed in the present study were associated with such clinical manifestations as headache, nausea, vomiting, tinnitus, unconsciousness, dizziness, loss of extremity movement, and ptosis. In most of the patients metastatic disease was diagnosed via magnetic resonance imaging (MRI). Figures 1 and 2 show different sections with brain metastasis of ovarian cancer. Figure 3 shows hystopathologic images of brain metastasis from different kinds of patients. Figures 1 and 2 clearly show that the location of metastatic spread varied (temporal, parietal, frontal lobe, and cerebellum).
While single intracranial metastasis occurred in 14 patients, multiple intracranial metastasis occurred in 11 patients. In 4 patients with ovarian cancer, 2 with cervical cancer, and 5 with endometrial cancer there was no recurrence other than brain involvement based on abdominal and thoracic screening. The other patients had multiple abdominal metastasis. Among these 5 patients that received radiation treatment, only 1 also received chemotherapy. There weren’t any differences in mean OS between the patients with brain metastasis that underwent surgical resection, medical therapy, and radiotherapy (P = 0.859), which was 2.2 months for all 25 patients. The patient with endometrial cancer and multiple intracranial metastasis underwent stereotaxic biopsy following gamma-knife radiotherapy, and was alive 19 months post treatment. In total, 11 patients with multiple intracranial metastasis and 6 with single intracranial metastasis were given palliative therapy.

4. DISCUSSION

The incidence of brain metastasis in clinical series of gynecological cancers is approximately 1% [14,15]. In the present study 9 of 657 patients with EOC developed brain metastasis (1.3%). The mean age of patients with EOC and brain metastasis varied from 50.4 to 59.3 years (range: 19-77 years) in different studies and 3% of these patients were stage III and IV [16]. In the present study 11 patients with EOC had serous adenocarcinoma—the most frequently encountered type, which is similar to previous findings [16]. Mean age of these 11 patients was 60 years (range: 45-74 year); all but 3 had advanced stage disease (stage III and IV),—7 had serous adenocarcinoma and 1 had clear cell adenocarcinoma.

Some researchers have suggested that the increased incidence of brain metastasis in EOC is related to the effectiveness of chemotherapy [15] or that cisplatin-based chemotherapy may contribute to an increase in the incidence of CNS involvement [4,14,17]. The blood-brain barrier (BBB) is thought to limit delivery of large in size hydrophilic drugs to the brain determining which agents and doses to be used [14]. Additionally, some researchers think that improvement in the efficacy of chemotherapy delays reoccurrence in the abdominal and pelvic cavity, but that the BBB blocks water-soluble cisplatin and lowers the concentration in the CNS, increasing the incidence of brain metastasis [18].

Brain metastasis usually occurs in patients with longer survivals. The maximum time from diagnosis of EOC to brain metastasis was 98 months and the longest survival period after brain metastasis was 7 years [19,20]. Tay et al. [21] reported that survival after brain metastasis was up to months, whereas Chen et al. [22] reported that the mean time from initial diagnosis of EOC to brain metastasis was 24.3 months and median survival after the discovery of CNS involvement was 3 months. In the present study mean survival after cytoreduction in stage III-IV cancer patients was 41.9 months (range: 27-79 months), and after brain metastasis was detected mean survival was limited to 2.92 months (rang: 0-6 months), regardless of treatment. Tay et al. [21] suggested that monitoring tumor recurrence based on the serum CA-125 level does not predict metastasis to the brain, as only 1 of 4 cases had elevated CA-125 at the time brain metastasis was diagnosed. All of the EOC patients with brain metastasis in the present study had elevated CA-125 (mean: 249 IU mL$^{-1}$; range: 44-735 IU mL$^{-1}$), as might occur in cases of recurrence in other regions of the body.

The prognosis of patients with brain metastasis is generally very poor without adjuvant treatment, as ranging from none to a few months of survival [20-23].The aim of treatment in patients with brain metastasis should be the
control of neurologic symptoms and improving quality of life. There are various treatment strategies, including corticosteroids, whole-brain radiotherapy (WBRT), surgery, radiosurgery, and chemotherapy. WBRT is the treatment of choice for most patients with brain metastasis of various malignancies; however, it can cause acute toxicity, such as skin irritation, alopecia, and otitis media. Single metastasis occurs in 43% of patients with EOC; approximately 50% of these patients are not surgical candidates because of extra cranial disease or tumor inaccessibility [24].

Treating single brain metastasis with surgical resection (with or without WBRT) improves OS [25]. Patchell et al. [26] reported that cases of solitary brain metastasis of any histological type treated with surgical excision plus WBRT had longer DFS, longer OS, and longer duration of functional independence, compared to those treated with WBRT alone. In patients with limited intracranial tumors, focal therapeutic modalities such as gamma-knife radiosurgery (GKS) may replace WBRT or surgery which delivers high-dose focal radiation and induces tumor necrosis while delivering minimal radiation to the surrounding normal brain tissue [23,25]. In all, 7 patients in the present study underwent surgical resection following WBRT. Patients that weren’t treated for metastatic disease because of their medical condition had 2 months of OS, whereas those that underwent surgical resection and radiotherapy had 5 months of OS, and 9 patients was still alive 8 months after the detection of CNS involvement.

4.1. Other Types of Gynecologic Malignancies

Few case reports and studies describe patients with endometrial carcinoma and brain metastasis [11]. The incidence of brain metastasis from endometrial carcinoma ranges from 0.3% to 1.4% [10,11]. The primary mechanism of spread was suggested to be dissemination to the lungs and to the brain via the pulmonary vasculature [27,28]. Many studies report that brain metastasis in endometrial cancer is usually associated with widespread disease, as in 6 patients in the present study [29,30]. Advanced stage, high grade, invasion of the lymphovascular space, and deep myometrial invasion are associated with brain metastasis [10, 27,30,31]. Tumor grade and deep myometrial invasion were correlated in the present study. The mean interval between diagnosis of primary tumor and CNS involvement is ranging from 0 to 52 months [10,28,32,33]. These results seem to be compatible with our study as 15.5 months is our time interval for CNS involvement to be found. In the present study mean OS after the diagnosis of brain metastasis was 17.5 months (1 patient was still alive when this report was written). In contrast, 2 cases treated with surgical resection following radiotherapy had long-term OS (82 and 83 months) after the development of brain metastasis [10,33]. One of the patients in the present was still alive (at the time this report was written) 30 months after stereotactic biopsy following GKS. Chura et al. reported that survival in patients treated with multimodal therapy (WBRT plus surgery, WBRT plus chemotherapy, or WBRT plus surgery and chemotherapy) was longer than in patients treated with WBRT only (P = 0.0001) and in patients that received no treatment (P = 0.009); no difference in OS was observed between the patients treated with WBRT only and those not treated. Other studies also support the survival advantage associated with multimodal therapy [10,32,34].

Brain metastasis from an MMMT of the uterus is very rare. To date, 4 cases of CNS involvement with MMMT metastasis have been reported [35,36]. The pathologic stage at diagnosis seems to be the most reliable predictor of prognosis in MMMT of uterine origin [36]. Surgical excision is considered the most effective treatment, whereas radiotherapy and various combinations of chemotherapy have achieved inconsistent results; however, Wong et al. observed that patients with MMMT of the uterus that received sequential adjuvant therapy—cisplatin and ifosfamide chemotherapy and radiotherapy—had longer survival compared with the control group without any adjuvant therapy [37]. The 4 cases mentioned above had mean survival of 2 months after the detection of brain metastasis; complete tumor resection or cranial radiotherapy alone didn’t provide a good prognosis [35,36,38]. Even though surgical resection or other mentioned therapies weren’t an option for the patient with MMMT in the present study because of her poor medical condition, OS after CNS involvement was 2 months. Based on limited data in the literature, we think that a poor prognosis in MMMT patients with brain metastasis is unavoidable.

Brain metastasis from cervical cancer occurs in 0.4%-1.2% of patients [39,40]. Mean OS after initial diagnosis of cervical cancer was 19.2 months and mean survival after diagnosis of brain metastasis ranged from 3 to 8 months [39-
41]. The treatment of brain metastasis usually involves radiation therapy, surgery, or both, depending on each patient’s clinical picture. Generally, surgical excision is used in cases with a solitary lesion or adjacent multiple metastases. Patients with non-adjacent, multiple, or inoperable lesions are usually treated with palliative WBRT [39,41]. In the present study’s patient the time from initial diagnosis to multiple metastatic CNS involvement was 4 months; nevertheless, survival was only 1 month after the discovery of brain metastasis. Though WBRT was planned, due to the patient’s poor medical condition she was given paclitaxel and carboplatin combination chemotherapy.

Brain metastasis from EOC and PPC is considered a rare occurrence. In a series of 24 patients (23 with EOC and 1 with PPC) Ratner et al. reported that OS was 37 months [42]. In the present study there was a significant difference in survival between EOC and PPC patients; OS in the EOC patients was 41.9 months versus 15 months in PPC patients. On the other hand, there was a small difference in survival after brain metastasis between the EOC and PPC patients (2.92 and 2 months, respectively), which was also reported by Ratner et al [42]. Surgical resection of cranial mass was not performed due to her medical condition. As in EOC, survival following brain metastasis in PPC is limited.

Distant spread occurs in 8% - 12% of patients with vulvar carcinomas. To date, brain metastasis from vulvar carcinoma has been reported in only 4 cases with different histopathological features. Our patient had squamous cell carcinoma and DFS of 36 months from initial diagnosis to secondary brain metastasis; following brain metastasis the patient survived for 12 d.

5. CONCLUSION

Although gynecologic cancers rarely metastasize to the brain, brain metastasis in such cases has a poor prognosis despite combined treatment modalities. Radiation therapy and surgery are effective in only partially removing masses. Unfortunately, on the basis of the known facts and our experience, chemotherapy—especially paclitaxel and carboplatin—functions only as palliation in such patients. Additional research on other chemotherapy regimens and targeted therapies in such patients with brain metastasis is warranted.

CONFLICT OF INTEREST AND FINANCIAL DISCLOSURE STATEMENTS

The authors declare that they have no conflict of interest. They also declare that they have not engaged in any financial relationship with any company whose product might be affected by the research described or with any company that makes or markets a competing product.

REFERENCES

Outcomes of 25 Gynecologic Cancer Patients with Brain Metastasis: A Single Center Experience


Copyright: © 2020 Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.